Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02225574
Title An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T)
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center, Novartis
Indications

acute leukemia

chronic myeloid leukemia

Therapies

Binimetinib + Nilotinib

Age Groups: adult
Covered Countries USA


No variant requirements are available.